List of publications on a keyword: «phencyclidine»


Медицина

Publication date: 16.02.2017
Evaluate the material Average score: 3 (Всего: 3)
Mrykhin Vladimir Valerievich , candidate of medical sciences , доцент
FSFEI of HE “Rostov State Medical University” of Russia Ministry of Health , Ростовская обл
Antsyborov Andrey Viktorovich , aspirant , психиатр, психиатр-нарколог
Medical center «Alpha Health» , Ростовская обл

«Psychiatric aspects of designer drugs and new psychoactive substances consumption»

Download an article

According to the authors, appeared not long ago new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, agonists of GABA (A/B) receptors have become a serious problem for both consumers and doctors. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, as well as «legal purity», which is declared by shadow producers. This indicates that there are some significant difficulties of laboratory typing of new surfactants. Designer drugs when ingested, can affect a range of neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA(A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.

Medicine

Publication date: 14.06.2019
Evaluate the material Average score: 0 (Всего: 0)
Antsyborov Andrey Viktorovich , aspirant , психиатр, психиатр-нарколог
Medical center «Alpha Health» , Ростовская обл
Dubatova Irina Vladimirovna , candidate of medical sciences , доцент
FSFEI of HE “Rostov State Medical University” of Russia Ministry of Health , Ростовская обл

«New psychoactive substances: psychiatrist's view»

Download an article

Appearing not long ago, new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, the GABA (A/B) receptors agonists, have become a serious problem for consumers and for physicians. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, and the «legal high» declared by the black manufacturers, which indicates that significant difficulties in a laboratory identification of new surfactants. Designer drugs, when ingested, can be influenced on many neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA (A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.